Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA

Journal of Immunological Methods

Volumn 387, Issue 1-2, 2013, Pages 157-166

  Tiwari, Ram P ^a   Jain, Anubhav ^a   Khan, Zakir ^b   Kumar, Pradeep ^a   Bhrigu, Vipul ^c   Bisen, Prakash S ^d  

^a Research and Development Centre   (India)

^b INSTITUT PASTEUR   (France)

^c Roche Diagnostic India Ltd   (India)

^d DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Cysteine bridge; HIV; Immunodominant antigens; Indian HIV isolates; Oligomeric peptide; V3 hypervariable loop

Indexed keywords

ANTIGEN P24; CYSTEINE; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 36; GLYCOPROTEIN GP 41; RP24 PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; V3 I PEPTIDE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY DETECTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INDIAN; MAJOR CLINICAL STUDY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AMINO ACID SEQUENCE; CYSTEINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HIV-2; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84871403022     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.10.009     Document Type: Article

References (42)

1. Baeten J.M., Chohan B., Lavreys L., Chohan V., McClelland R.S., Certain L., Mandaliya K., Jaoko W., Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 2007, 195:1177.
2. Bisen P.S., Garg S.K., Tiwari R.P., Tagore P.R.N., Tiwari D., Chandra R., Karnik R., Thaker N., Desai N., Ghosh P.K., Fraziano M., Colizzi V. Analysis of shotgun expression library of Mycobacterium tuberculosis genome for immunodominant polypeptide: potential use in serodiagnosis. Clin. Diagn. Lab. Immunol. 2003, 6:1051.
3. Bobkov A., Kazennova E.V., Selimova L.M., Khanina T.A., Ryabov G.S., Bobkova M., Sukhanova A.L., Kravchenko A.V., Ladnaya N.N., Weber J.N., Pokrovsky V.V. Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J. Med. Virol. 2004, 74:191.
4. Briand J.P., Muller S., van Regenmortel M.H.V. Synthetic peptides as antigen: pitfalls of conjugation methods. J. Immunol. Methods 1985, 78:59.
5. Buonaguro L., Tornesello M.L., Buonaguro F.M. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 2007, 81:10209.
6. Constantine N.T. Serologic tests for the retroviruses: approaching a decade of evolution. AIDS 1993, 7:1.
7. Crofts N., Maskill W., Gust I.D. Evaluation of enzyme-linked immunosorbent assays: a method of data analysis. J. Virol. Methods 1988, 22:51.
8. Desai S., Bates H., Michalski F.J. Detection of antibody to HIV-1 in urine. Lancet 1991, 337:183.
9. Gallaher W.R. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987, 50:327.
10. Geretti A.M. HIV-1 subtypes: epidemiology and significance for HIV management. Curr. Opin. Infect. Dis. 2006, 19:1.
11. Hell A.J., Crommelin D.J., Hennink W.E., Mastrobattista E. Stabilization of peptide vesicles by introducing inter-peptide disulfide bonds. Pharm. Res. 2009, 26:2186.
12. Janssens W., Fransen K., Loussert-Ajaka I. Diagnosis of HIV-1 group O infection by polymerase chain reaction. Lancet 1995, 346:451.
13. Janssens W., Buvé A., Nkengasong J.N. The puzzle of HIV-1 subtypes in Africa. AIDS 1997, 11:705.
14. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34:595.
15. Kartikeyan S., Bharmal R.N., Tiwari R.P., Bisen P.S. HIV and AIDS: Basic Elements and Priorities 2007, 428. Springer, Dordrecht (The Netherlands), (ISBN-10: 1-4020-5788-1, ISBN-13: 978-1-4020-5788-5).
16. Kerchoven I.V., Vercauteren F., Piot P., Groen G.V.D. Comparative evaluation of 36 assays for detecting antibodies to HIV. Bull. World Health Organ. 1991, 69:753.
17. Kliger Y., Levanon E.Y. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiol. 2003, 3:20.
18. Le Vu S., Le Strat Y., Barin F., Pillonel J., Cazein F., Bousquet V., Brunet S., Thierry D., Semaille C., Meyer L., Desenclos J.C. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect. Dis. 2010, 10:682.
19. Maskill W.J., Crofts N., Waldman E., Healey D.S., Howard T.S., Silvester C., Gust I.D. An evaluation of competitive and second generation ELISA screening tests for antibody to HIV. J. Virol. Methods 1988, 22:61.
20. Mauclere P., Loussert-Ajaka I., Damond F., Fagot P., Souquieres S., Lobe M.M., Keou F.X.M., Barre-Sinoussi F., Saragosti S., Brun-Vezinet F., Simon F. Serological and Virological characterization of HIV-1 group O infection in Cameroon. AIDS 1997, 11:445.
21. Merrifield R.B. Solid phase synthesis. Science 1986, 232:341.
22. Monno L., Saracino A., Scudeller L., Punzi G., Brindicci G., Altamura M., Lagioia A., Ladisa N., Angarano G. Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob. Agents Chemother. 2011, 55:5078.
23. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nádas A., Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 2000, 74:7096.
24. Pandori M.W., Hackett J., Louie B., Vallari A., Dowling T., Liska S., Klausner J.D. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J. Clin. Microbiol. 2009, 47:2639.
25. Patel M.B., Hoffman N.G., Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 2008, 82:903.
26. Peeters M., Nkengasong J., Willems B., Karita E., Delaporte E., Van den Haesevelde M., Piot P., van der Groen G. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions. AIDS 1994, 8:1657.
27. Pollakis G., Abebe A., Kliphuis A., De Wit T.F., Fisseha B., Tegbaru B., Tesfaye G., Negassa H., Mengistu Y., Fontanet A.L., Cornelissen M., Goudsmit J. Recombination of HIV type 1C (C'/C") in Ethiopia: possible link of EthHIV-1C' to subtype C sequences from the high-prevalence epidemics in India and Southern Africa. AIDS Res. Hum. Retroviruses 2003, 19:999.
28. Singh S.K., Bisen P.S. Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine 2006, 24:4161.
29. Singh S.K., Shah N.K., Bisen P.S. A synthetic gag p24 epitope chemically coupled to BSA through a deca-alanine peptide enhances HIV-1 serodiag- nostic ability by several folds. AIDS Res. Hum. Retroviruses 2007, 23:153.
30. Sreepian A., Permmongkol J., Kantakamalakul W., Siritantikorn S., Tanlieng N., Sutthent N. HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses. J. Immune Based Ther. Vaccines 2009, 7:5.
31. Stetler H.C., Granade T.C., Nunez C.A., Meza R., Terrell S., Amador L., George J.R. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. AIDS 1997, 11:369.
32. Stewart J.M., Young J.D. Solid Phase Peptide Synthesis 1984, 1. Pierce Chemical Company, Rockford (Illinois, USA). 2nd edn.
33. Subbarao S., Luo C.-C., Limpakarnjanarat K., Bhumisawasdi J., Young N.L., Mastro T.D., Schochetman G., Kalish M.L. Evaluation of oligonucleotide probes for the determination of the two major HIV-1 env subtypes in Thailand. AIDS 1996, 10:350.
34. Taylor B.S., Sobieszczyk M.E., McCutchan F.E., Hammer S.M. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 2008, 358:1590.
35. Tiwari R.P., Tiwari D., Garg S.K., Chandra R., Bisen P.S. Glycolipids of Mycobacterium tuberculosis strain H37Rv are potential serological markers for diagnosis of active tuberculosis. J. Clin. Diagn. Lab. Immunol. 2005, 12:465.
36. Tiwari R.P., Hattikudur N.S., Bharmal R.N., Kartikeyan S., Deshmukh N.M., Bisen P.S. Modern approaches to a rapid diagnosis of tuberculosis: promises and challenges ahead. Tuberculosis 2007, 87:193.
37. Toman K. Sensitivity, specificity and predictive value of diagnostic tests. Bull. Int. Tuberculosis 1981, 56:19.
38. Tripathy S.P., Kumar A., Manivel A., Panda S.K., Rao K.V.S. Design and synthesis of a self-assembling peptide derived from the envelope proteins of HIV type 1. An approach to heterovalent immunogens. J. Immunol. 1992, 6(148):4012.
39. UNAIDS/WHO Global HIV/AIDS response-Epidemic update and health sector progress towards Universal Access-Progress report 2011 2011.
40. Vranken W.F., Fant F., Budesinsky M., Borremans F.A.M. Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20 per cent trifluoroethanol/water solution. Eur. J. Biochem. 2001, 268:2620.
41. Walker P.R., Cilliers T., Choge I.A., Taylor N., Cohen S.S., Morris L. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J. Med. Virol. 2006, 78:1262.
42. WHO. Acquired Immunodeficiency Syndrome (AIDS) Proposed criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. Wkly. Epidemiol. Rec. 1990, 65:281.